



For immediate release

Precision Biopsy Raises \$33.6 Million to Accelerate the Commercial Expansion of its ClariCore™ Biopsy System

- Funds raised will accelerate commercial expansion of Precision Biopsy's ClariCore Biopsy System, designed to provide accurate real-time classification of prostate tissue during biopsy procedures, and its Focal Therapy program which seeks to provide targeted localized therapy to reduce complications and improve outcomes.

Aurora, Colorado (Oct. 5, 2015) – Precision Biopsy announced that it successfully raised \$33.6 million in new equity investments as the company embarks on a global commercialization strategy for its ClariCore™ Biopsy System, a device platform designed to provide accurate, real-time classification of prostate tissue during biopsy procedures.

The company also plans to accelerate the development of its Focal Therapy program, which seeks to provide targeted, localized therapy to the prostate gland by using the same optical tissue-targeting technology found in the ClariCore system. Woodford Investment Management (Woodford) led this round of financing, which included Precision Biopsy's parent company, Allied Minds (LSE: ALM), and demonstrates the continued support for the business and these growth initiatives.

"We are delighted to receive the support of leading institutional investors as we prepare to bring our ClariCore Biopsy System to market," said Amir Tehrani, Chief Executive Officer of Precision Biopsy. "We believe that the ClariCore system will help to improve the diagnostic process for millions of patients who undergo biopsy procedures each year to monitor for prostate cancer, the second-most deadly cancer in men after lung cancer."

More than 2 million men worldwide undergo transrectal ultrasound (TRUS)-guided prostate biopsies each year due to various risk factors, including elevated PSA levels, physical exam abnormalities, and family history. Yet fewer than 10 percent of the 12 million biopsy core samples that are analyzed come back positive for cancer — at a cost of nearly \$1 billion dollars in the U.S. alone. These TRUS-guided prostate biopsies also miss as much as 30 percent of cancers that require therapy. Reducing

that error rate could have measurable impact: In the U.S., about 28,000 men die each year from prostate cancer, according to the American Cancer Society.

The ClariCore system is designed to perform spectral analysis during a biopsy to rapidly classify whether tissue in the prostate is normal or suspicious. Equipped with an optical fiber and companion console, ClariCore provides *in-vivo* tissue classification that seeks to minimize the number of core samples taken by up to 90 percent, while offering actionable diagnostic information.

Omar Amirana, MD, Senior Vice President at Allied Minds, commented, "Precision Biopsy aims to offer a win-win to healthcare systems worldwide: physicians and patients will receive real-time information and detection, enabling better patient management decisions while helping the healthcare system overall run more efficiently and cost effectively. This successful fundraising will help to accelerate its commercial expansion."

Precision Biopsy's application of the ClariCore technology in its Focal Therapy program also aims to reduce complications and improve outcomes for prostate cancer patients. The use of focal therapy has traditionally been limited because of an inability to identify the location of a cancer tumor or how broadly it's spread within the prostate gland. Precision Biopsy's plans to offer 3-D mapping of the prostate tissue are designed to provide better insight into a cancerous area. Urologists would have the ability to treat patients in one session, potentially reducing the need for radical prostatectomy procedures and preserving healthy tissue.

More information about Precision Biopsy can be found at www.precisionbiopsy.com.

About Precision Biopsy

Precision Biopsy, LLC, a subsidiary of Allied Minds (LSE: ALM), aims to develop and commercialize a novel technology for the accurate real-time classification of tissue during prostate biopsies – a procedure that is performed in an estimated 1.75 million patients each year in the U.S. and Europe. It is also developing a Focal Therapy system, which incorporates the ClariCore technology. The company's diagnostic technology, licensed from the University of Colorado, uses advanced spectroscopy imaging techniques in combination with tissue biopsy. After developing a first-generation system in 2011, Precision Biopsy evaluated human subjects in 2012. The success of that first human study led Precision Biopsy to focus on developing its next-generation product, the ClariCore Optical Biopsy System™, as it prepares for global commercialization. More information about Precision Biopsy can be found at: www.precisionbiopsy.com.

About Allied Minds

Allied Minds (LSE: ALM) is an innovative U.S. science and technology development

and commercialization company. Operating since 2006, Allied Minds forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

Allied Minds Forward-Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the company's regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law, regulatory requirement, the Listing Rules and the Disclosure and Transparency Rules, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts:

US

Christine Dunn
ArcPoint Strategic Communications
cdunn@arcpointstrategy.com
617.484.1660 x101

UK

Ben Atwell, Matthew Cole
FTI Consulting
+44 (0) 20 3727 1000